The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Clinical trials and novel agents under investigation in T-cell lymphoma
In this video, Swaminathan P. Iyer, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses ongoing clinical trials in T-cell lymphoma, drawing focus on the Alliance A059102 trial (NCT04803201), and various studies evaluating the use of CAR-T cells in the relapsed/refractory (R/R) setting. Dr Iyer also comments on novel agents under investigation in T-cell lymphoma, including novel PI3K inhibitors, and the importance of further research in this space. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
